PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 05: MARKET SIZING • Market definition • Market sizing 2017 • Market size and forecast 2017-2022 PART 06: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 07: PIPELINE LANDSCAPE PART 08: MARKET SEGMENTATION BY PRODUCT TYPE • Segmentation by product type • Comparison by product type • Anti-VEGF – Market size and forecast 2017-2022 • Corticosteroid – Market size and forecast 2017-2022 • Others – Market size and forecast 2017-2022 • Market opportunity by product type PART 09: CUSTOMER LANDSCAPE PART 10: REGIONAL LANDSCAPE • Geographical segmentation • Regional comparison • Americas – Market size and forecast 2017-2022 • EMEA – Market size and forecast 2017-2022 • APAC – Market size and forecast 2017-2022 • Market opportunity PART 11: DECISION FRAMEWORK PART 12: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 13: MARKET TRENDS PART 14: VENDOR LANDSCAPE • Overview • Landscape disruption PART 15: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • ALLERGAN • Alimera Sciences • Bausch Health • F. Hoffmann-La Roche • Regeneron Pharmaceuticals PART 16: APPENDIX • List of abbreviations Exhibit 01: Parent market Exhibit 02: Global diabetic macular edema treatment market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2017 Exhibit 07: Validation techniques employed for market sizing 2017 Exhibit 08: Global diabetic macular edema treatment market – Market size and forecast 2017-2022 ($ mn) Exhibit 09: Global diabetic macular edema treatment market – Year-over-year growth 2018-2022 (%) Exhibit 10: Five forces analysis 2017 Exhibit 11: Five forces analysis 2022 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2017 Exhibit 18: Key clinical trial candidates for the treatment of diabetic macular edema Exhibit 19: Key clinical trial candidates for the treatment of diabetic macular edema Exhibit 20: Comparison by product type Exhibit 21: Anti-VEGF – Market size and forecast 2017-2022 ($ mn) Exhibit 22: Anti-VEGF – Year-over-year growth 2018-2022 (%) Exhibit 23: Corticosteroid – Market size and forecast 2017-2022 ($ mn) Exhibit 24: Corticosteroid – Year-over-year growth 2018-2022 (%) Exhibit 25: Others – Market size and forecast 2017-2022 ($ mn) Exhibit 26: Others – Year-over-year growth 2018-2022 (%) Exhibit 27: Market opportunity by product type Exhibit 28: Customer landscape Exhibit 29: Global diabetic macular edema treatment market by geography – Market share 2017-2022 (%) Exhibit 30: Regional comparison Exhibit 31: Americas – Market size and forecast 2017-2022 ($ mn) Exhibit 32: Americas – Year-over-year growth 2018-2022 (%) Exhibit 33: Top 3 countries in Americas Exhibit 34: EMEA – Market size and forecast 2017-2022 ($ mn) Exhibit 35: EMEA – Year-over-year growth 2018-2022 (%) Exhibit 36: Top 3 countries in EMEA Exhibit 37: APAC – Market size and forecast 2017-2022 ($ mn) Exhibit 38: APAC – Year-over-year growth 2018-2022 (%) Exhibit 39: Top 3 countries in APAC Exhibit 40: Market opportunity Exhibit 41: Vendor landscape Exhibit 42: Landscape disruption Exhibit 43: Vendors covered Exhibit 44: Vendor classification Exhibit 45: Market positioning of vendors Exhibit 46: ALLERGAN: Overview Exhibit 47: ALLERGAN – Business segments Exhibit 48: ALLERGAN – Organizational development Exhibit 49: ALLERGAN – Geographic focus Exhibit 50: ALLERGAN – Segment focus Exhibit 51: ALLERGAN – Key offerings Exhibit 52: ALLERGAN – Key customers Exhibit 53: Alimera Sciences: Overview Exhibit 54: Alimera Sciences – Business segments Exhibit 55: Alimera Sciences – Organizational developments Exhibit 56: Alimera Sciences – Segment focus Exhibit 57: Alimera Sciences – Key offerings Exhibit 58: Alimera Sciences – Key customers Exhibit 59: Bausch Health: Overview Exhibit 60: Bausch Health – Business segments Exhibit 61: Bausch Health – Organizational developments Exhibit 62: Bausch Health – Geographic focus Exhibit 63: Bausch Health – Segment focus Exhibit 64: Bausch Health – Key offerings Exhibit 65: Bausch Health – Key customers Exhibit 66: F. Hoffmann-La Roche: Overview Exhibit 67: F. Hoffmann-La Roche – Business segments Exhibit 68: F. Hoffmann-La Roche – Organizational developments Exhibit 69: F. Hoffmann-La Roche – Geographic focus Exhibit 70: F. Hoffmann-La Roche – Segment focus Exhibit 71: F. Hoffmann-La Roche – Key offerings Exhibit 72: F. Hoffmann-La Roche – Key customers Exhibit 73: Regeneron Pharmaceuticals: Overview Exhibit 74: Regeneron Pharmaceuticals – Business segments Exhibit 75: Regeneron Pharmaceuticals – Organizational development Exhibit 76: Regeneron Pharmaceuticals – Segment focus Exhibit 77: Regeneron Pharmaceuticals – Key offerings Exhibit 78: Regeneron Pharmaceuticals – Key customers

ALLERGAN Alimera Sciences Bausch Health F. Hoffmann-La Roche Regeneron Pharmaceuticals